GeneThera Inc
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacte… Read more
GeneThera Inc (GTHR) - Total Assets
Latest total assets as of December 2022: $6.30K USD
Based on the latest financial reports, GeneThera Inc (GTHR) holds total assets worth $6.30K USD as of December 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GeneThera Inc - Total Assets Trend (1997–2022)
This chart illustrates how GeneThera Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GeneThera Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
GeneThera Inc's total assets of $6.30K consist of 16.2% current assets and 83.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1997–2022)
This chart illustrates how GeneThera Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneThera Inc's current assets represent 16.2% of total assets in 2022, a decrease from 46.3% in 1997.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2022, down from 1.5% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 1997.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GeneThera Inc Competitors by Total Assets
Key competitors of GeneThera Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
GeneThera Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - GeneThera Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - GeneThera Inc is currently not profitable relative to its asset base.
GeneThera Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 0.01 |
| Quick Ratio | 0.00 | 0.00 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.18 Million | $ -8.18 Million | $ -7.15 Million |
GeneThera Inc - Advanced Valuation Insights
This section examines the relationship between GeneThera Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $6.30K |
| Market Capitalization | $2.92K USD |
Valuation Analysis
Below Book Valuation: The market values GeneThera Inc's assets below their book value (0.46 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: GeneThera Inc's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for GeneThera Inc (1997–2022)
The table below shows the annual total assets of GeneThera Inc from 1997 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $6.30K | 0.00% |
| 2021-12-31 | $6.30K | -45.59% |
| 2020-12-31 | $11.58K | -45.24% |
| 2019-12-31 | $21.15K | -89.74% |
| 2018-12-31 | $206.05K | 0.00% |
| 2017-12-31 | $206.05K | -- |
| 2016-12-31 | $0.00 | -- |
| 2015-12-31 | $146.11K | +847.30% |
| 2014-12-31 | $15.42K | -57.27% |
| 2013-12-31 | $36.09K | -40.42% |
| 2012-12-31 | $60.58K | +21.61% |
| 2011-12-31 | $49.81K | -77.54% |
| 2008-12-31 | $221.79K | -39.12% |
| 2007-12-31 | $364.31K | -7.68% |
| 2006-12-31 | $394.61K | -7.99% |
| 2005-12-31 | $428.86K | -53.06% |
| 2004-12-31 | $913.64K | +13.25% |
| 2003-12-31 | $806.76K | +148.60% |
| 2002-12-31 | $324.52K | +231.69% |
| 2001-12-31 | $97.84K | -48.51% |
| 2000-12-31 | $190.00K | -62.98% |
| 1999-12-31 | $513.22K | -16.20% |
| 1998-12-31 | $612.47K | -8.59% |
| 1997-12-31 | $670.00K | -- |